These findings establish glycine as a signaling metabolite that activates a receptor-calcium axis to maintain β-cell function, offering a mechanistic rationale for targeting GLRA1 or dietary glycine in diabetes therapy. This evidence concerns the gene GLRA1 and diabetes mellitus.